• Vaccine Name: rMVTT-SIV-gpe
• Target Pathogen: Human Immunodeficiency Virus
• Target Disease: Acquired Immunodeficiency Syndrome (AIDS)
• Vaccine Ontology ID: VO_0004760
• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: Baboon
• env from SIV gene engineering:
  • Type: Recombinant vector construction
  • Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
  • Detailed Gene Information: Click Here.
• Pol SIV gene engineering:
  • Type: Recombinant vector construction
  • Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
  • Detailed Gene Information: Click Here.
• Pol SIV gene engineering:
  • Type: Recombinant vector construction
  • Description: A recombinant modified replicating vaccinia virus Tiantan strain (MVTTSIVgpe) and a recombinant, nonreplicating adenovirus type 5 strain (Ad5SIVgpe) expressing the SIVmac239 Gag, Pol, and Env structural proteins were generated (Sun et al., 2013).
  • Detailed Gene Information: Click Here.
• Vector:
  • Vector name:
  • VO vector ID: VO_0001109
  • Description: (Sun et al., 2013)
• Preparation: (Sun et al., 2013) a modified replicating vaccinia virus Tiantan strain (MVTT(SIVgpe))
• Immunization Route: Intramuscular injection (i.m.)

Monkey Response

• Vaccination Protocol: Eight monkeys were divided into two groups: (i) four monkeys received the MVTTioin+Adim testing regimen as in study I, and (ii) four monkeys received an empty MVTT control vector (10^9 PFU) through intraoral (0.5 ml) and intranasal (0.5 ml) routes and an empty Ad5 control vector (10^11 vp in 1 ml of PBS) through intramuscular injection (Sun et al., 2013).
• Vaccine Immune Response Type: VO_0003057
• Challenge Protocol: At either week 30 after the initial vaccination or week 24 after the final vaccination, each animal was challenged intrarectally with 5 × 10^5 50% tissue culture infective doses (TCID50) of Chinese rhesus monkey-adapted and neutralization-resistant SIVmac239. In all cases, the challenge virus stock was administered in 1 ml of PBS (Sun et al., 2013).
• Efficacy: The reductions in peak and set-point viral loads were significant in most animals, with one other animal being protected fully from high-dose intrarectal inoculation of SIV(mac239). Furthermore, the animals vaccinated with this regimen were healthy, while ~75% of control animals developed simian AIDS. The protective effects correlated with the vaccine-elicited SIV-specific CD8(+) T cell responses against Gag and Pol (Sun et al., 2013).